FourThought Financial’s Sarepta Therapeutics SRPT Stock Holding History

FourThought Financial’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$33K	Buy	297 +90	+43%	+$9.07K	﹤0.01%	734
2022 Q2	$16K	Hold	207	–	–	﹤0.01%	917
2022 Q1	$16K	Sell	207 -57	-22%	-$4.37K	﹤0.01%	958
2021 Q4	$24K	Sell	264 -90	-25%	-$7.69K	﹤0.01%	885
2021 Q3	$32K	Hold	354	–	–	﹤0.01%	828
2021 Q2	$27K	Sell	354 -32	-8%	-$2.43K	﹤0.01%	875
2021 Q1	$28K	Sell	386 -31	-7%	-$2.86K	﹤0.01%	834
2020 Q4	$71K	Buy	+417	New	+$61.8K	0.01%	567

Other funds holding SRPT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

FourThought Financial's SRPT Position: Q3 2022 in Review

FourThought Financial increased its Sarepta Therapeutics (SRPT) stake by 43% in Q3 2022, buying an estimated $9.07K and bringing the position to 297 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #734.

FourThought Financial first reported a position in SRPT in Q4 2020 and has held it in 8 quarters since. The position peaked at $71K in Q4 2020. 376 funds tracked by Wall St. Rank hold SRPT as of Q3 2022.

FourThought Financial held 297 shares of Sarepta Therapeutics worth $33K as of Q3 2022.
FourThought Financial bought 90 Sarepta Therapeutics shares in Q3 2022, an estimated $9.07K.
Sarepta Therapeutics made up ﹤0.01% of FourThought Financial's portfolio in Q3 2022, its #734 holding.
FourThought Financial first reported a position in Sarepta Therapeutics in Q4 2020 and has held it in 8 quarters since.
FourThought Financial's Sarepta Therapeutics position peaked at $71K in Q4 2020.
376 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.